Urolithin B alleviates Helicobacter pylori-induced inflammation and oxidative stress in mice.
Humans
Animals
Mice
Helicobacter pylori
Helicobacter Infections
/ microbiology
Gastric Mucosa
/ microbiology
Anti-Bacterial Agents
/ pharmacology
Clarithromycin
/ therapeutic use
Metronidazole
/ pharmacology
Oxidative Stress
Inflammation
/ drug therapy
Antioxidants
/ pharmacology
Anti-Inflammatory Agents
/ pharmacology
Drug Therapy, Combination
Helicobacter pylori
anti-inflammatory
antioxidant
gastrointestinal disease
natural metabolite
urolithin B
Journal
Helicobacter
ISSN: 1523-5378
Titre abrégé: Helicobacter
Pays: England
ID NLM: 9605411
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
revised:
08
08
2023
received:
16
06
2023
accepted:
08
08
2023
medline:
22
11
2023
pubmed:
25
8
2023
entrez:
25
8
2023
Statut:
ppublish
Résumé
Helicobacter pylori is one of the most common chronic bacterial infections. Active eradication of H. pylori infection is rare due to the fact that most infected patients are asymptomatic and the use of large amounts of antibiotics in eradication therapy leads to severe side effects. Urolithin B (UB) is an additional major intestinal metabolite of ellagic acid (EA), which has been shown to possess anti-inflammatory, antioxidant, and antiapoptotic biological activities. Preventing the incidence of H. pylori-related gastric disease and reducing the damage to the host by H. pylori is a current approach to control H. pylori infection. In this study, we explored the effect of UB on H. pylori infection. The effects of UB on inflammation and oxidative stress induced by H. pylori in vivo and in vitro were investigated by qPCR, ELISA, HE staining, IHC staining, etc. RESULTS: UB reduced the adhesion and colonization of H. pylori and improved H. pylori-induced inflammation and oxidative stress in vivo and in vitro. Moreover, UB had better anti-inflammatory and antioxidant effects than clarithromycin (CLR) and metronidazole (MET). In addition to inhibiting the secretion of CagA, UB reduced tissue damage by H. pylori infection. UB was effective in improving damage caused by H. pylori.
Sections du résumé
BACKGROUND
BACKGROUND
Helicobacter pylori is one of the most common chronic bacterial infections. Active eradication of H. pylori infection is rare due to the fact that most infected patients are asymptomatic and the use of large amounts of antibiotics in eradication therapy leads to severe side effects. Urolithin B (UB) is an additional major intestinal metabolite of ellagic acid (EA), which has been shown to possess anti-inflammatory, antioxidant, and antiapoptotic biological activities. Preventing the incidence of H. pylori-related gastric disease and reducing the damage to the host by H. pylori is a current approach to control H. pylori infection. In this study, we explored the effect of UB on H. pylori infection.
MATERIALS AND METHODS
METHODS
The effects of UB on inflammation and oxidative stress induced by H. pylori in vivo and in vitro were investigated by qPCR, ELISA, HE staining, IHC staining, etc. RESULTS: UB reduced the adhesion and colonization of H. pylori and improved H. pylori-induced inflammation and oxidative stress in vivo and in vitro. Moreover, UB had better anti-inflammatory and antioxidant effects than clarithromycin (CLR) and metronidazole (MET). In addition to inhibiting the secretion of CagA, UB reduced tissue damage by H. pylori infection.
CONCLUSIONS
CONCLUSIONS
UB was effective in improving damage caused by H. pylori.
Substances chimiques
urolithin B
0
Anti-Bacterial Agents
0
Clarithromycin
H1250JIK0A
Metronidazole
140QMO216E
Antioxidants
0
Anti-Inflammatory Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13016Subventions
Organisme : Higher Education Personnel Training and Teaching Reform Project of Sichuan Province
ID : JG2021-42
Organisme : Sichuan Science and Technology Program
ID : 2023YFS0156
Organisme : Sichuan Science and Technology Program
ID : 2023YFSY0055
Organisme : Training Plan 2.0 for Top Students in Basic Sciences
ID : 20212079
Informations de copyright
© 2023 John Wiley & Sons Ltd.
Références
Moccia F, Liberti D, Giovando S, et al. Chestnut wood mud as a source of ellagic acid for dermo-cosmetic applications. Antioxidants (Basel). 2022;11:1681.
Kondratyuk TP, Adrian JA, Wright B, et al. Evidence supporting the conceptual framework of cancer chemoprevention in canines. Sci Rep. 2016;6:26500.
Garcia-Villalba R, Beltran D, Espin JC, Selma MV, Tomas-Barberan FA. Time course production of urolithins from ellagic acid by human gut microbiota. J Agric Food Chem. 2013;61:8797-8806.
Manach C, Scalbert A, Morand C, Rémésy C, Jiménez L. Polyphenols: food sources and bioavailability. Am J Clin Nutr. 2004;79:727-747.
Rechner AR, Kuhnle G, Bremner P, Hubbard GP, Moore KP, Rice-Evans CA. The metabolic fate of dietary polyphenols in humans. Free Radic Biol Med. 2002;33:220-235.
Rechner AR, Smith MA, Kuhnle G, et al. Colonic metabolism of dietary polyphenols: influence of structure on microbial fermentation products. Free Radic Biol Med. 2004;36:212-225.
Scalbert A, Morand C, Manach C, Rémésy C. Absorption and metabolism of polyphenols in the gut and impact on health. Biomed Pharmacother. 2002;56:276-282.
Cerdá B, Periago P, Espín J, Tomás-Barberán F. Identification of urolithin a as a metabolite produced by human colon microflora from ellagic acid and related compounds. J Agric Food Chem. 2005;53:5571-5576.
Huang X, Gao H, Jiang X, Zheng Z. Urolithin B, a gut microbiota metabolite, reduced susceptibility to myocardial arrhythmic predisposition after hypoxia. Dis Markers. 2022;2022:6517266.
Yuan T, Ma H, Liu W, et al. Pomegranate's neuroprotective effects against Alzheimer's disease are mediated by urolithins, its ellagitannin-gut microbial derived metabolites. ACS Chem Neurosci. 2016;7:26-33.
Ismail T, Calcabrini C, Diaz AR, et al. Ellagitannins in cancer chemoprevention and therapy. Toxins (Basel). 2016;8:151.
Tomás-Barberán FA, González-Sarrías A, García-Villalba R, et al. Urolithins, the rescue of "old" metabolites to understand a "new" concept: metabotypes as a nexus among phenolic metabolism, microbiota dysbiosis, and host health status. Mol Nutr Food Res. 2017;61:1500901.
Tomás-Barberán FA, García-Villalba R, González-Sarrías A, Selma MV, Espín JC. Ellagic acid metabolism by human gut microbiota: consistent observation of three urolithin phenotypes in intervention trials, independent of food source, age, and health status. J Agric Food Chem. 2014;62:6535-6538.
Cortés-Martín A, García-Villalba R, González-Sarrías A, et al. The gut microbiota urolithin metabotypes revisited: the human metabolism of ellagic acid is mainly determined by aging. Food Funct. 2018;9:4100-4106.
Lee G, Park JS, Lee EJ, Ahn JH, Kim HS. Anti-inflammatory and antioxidant mechanisms of urolithin B in activated microglia. Phytomedicine. 2019;55:50-57.
Piwowarski JP, Kiss AK, Granica S, Moeslinger T. Urolithins, gut microbiota-derived metabolites of ellagitannins, inhibit LPS-induced inflammation in RAW 264.7 murine macrophages. Mol Nutr Food Res. 2015;59:2168-2177.
Savi M, Bocchi L, Mena P, et al. In vivo administration of urolithin A and B prevents the occurrence of cardiac dysfunction in streptozotocin-induced diabetic rats. Cardiovasc Diabetol. 2017;16:80.
Chen P, Chen F, Lei J, Wang G, Zhou B. The gut microbiota metabolite urolithin B improves cognitive deficits by inhibiting Cyt C-mediated apoptosis and promoting the survival of neurons through the PI3K pathway in aging mice. Front Pharmacol. 2021;12:768097.
Lv MY, Shi CJ, Pan FF, et al. Urolithin B suppresses tumor growth in hepatocellular carcinoma through inducing the inactivation of Wnt/β-catenin signaling. J Cell Biochem. 2019;120:17273-17282.
Fontham ET. Infectious diseases and global cancer control. CA Cancer J Clin. 2009;59:5-7.
Guo L, Zhang F, Wang S, et al. Oral immunization with a M cell-targeting recombinant L. Lactis vaccine LL-plSAM-FVpE stimulate protective immunity against H. pylori in mice. Front Immunol. 2022;13:918160.
Kocsmár É, Buzás GM, Szirtes I, et al. Primary and secondary clarithromycin resistance in Helicobacter pylori and mathematical modeling of the role of macrolides. Nat Commun. 2021;12:2255.
Hutton ML, D'Costa K, Rossiter AE, et al. A Helicobacter pylori homolog of eukaryotic flotillin is involved in cholesterol accumulation, epithelial cell responses and host colonization. Front Cell Infect Microbiol. 2017;7:219.
Oleastro M, Ménard A. The role of Helicobacter pylori outer membrane proteins in adherence and pathogenesis. Biology (Basel). 2013;2:1110-1134.
Miernyk KM, Bulkow LR, Gold BD, et al. Prevalence of Helicobacter pylori among Alaskans: factors associated with infection and comparison of urea breath test and anti-Helicobacter pylori IgG antibodies. Helicobacter. 2018;23:e12482.
Zarzecka U, Modrak-Wójcik A, Figaj D, et al. Properties of the HtrA protease from bacterium Helicobacter pylori whose activity is indispensable for growth under stress conditions. Front Microbiol. 2019;10:961.
Choi KW, Joo M, Kim HS, Lee WY. Synchronous triple occurrence of MALT lymphoma, schwannoma, and adenocarcinoma of the stomach. World J Gastroenterol. 2017;23:4127-4131.
Chen M, Reed RR, Lane AP. Chronic inflammation directs an olfactory stem cell functional switch from neuroregeneration to immune defense. Cell Stem Cell. 2019;25:501-513.e505.
Monkkonen T, Debnath J. Inflammatory signaling cascades and autophagy in cancer. Autophagy. 2018;14:190-198.
Gisbert JP. The recurrence of Helicobacter pylori infection: incidence and variables influencing it. A critical review. Am J Gastroenterol. 2005;100:2083-2099.
Scribano ML, Prantera C. Antibiotics and inflammatory bowel diseases. Dig Dis. 2013;31:379-384.
Yee JK. Helicobacter pylori colonization of the oral cavity: a milestone discovery. World J Gastroenterol. 2016;22:641-648.
Yee KC, Wei MH, Yee HC, Everett KD, Yee HP, Hazeki-Talor N. A screening trial of Helicobacter pylori-specific antigen tests in saliva to identify an oral infection. Digestion. 2013;87:163-169.
Zhao LJ, Huang YQ, Chen BP, et al. Helicobacter pylori isolates from ethnic minority patients in Guangxi: resistance rates, mechanisms, and genotype. World J Gastroenterol. 2014;20:4761-4770.
Jonkers D, Stockbrügger R. Review article: probiotics in gastrointestinal and liver diseases. Aliment Pharmacol Ther. 2007;26(Suppl 2):133-148.
Cano A, Ettcheto M, Espina M, et al. State-of-the-art polymeric nanoparticles as promising therapeutic tools against human bacterial infections. J Nanobiotechnol. 2020;18:156.
Wu PC, Wu CJ, Lin CJ, Wu VC. Long-term risk of upper gastrointestinal hemorrhage after advanced AKI. Clin J Am Soc Nephrol. 2015;10:353-362.
Yu ZH, Cao M, Wang YX, et al. Urolithin A attenuates Helicobacter pylori-induced damage in vivo. J Agric Food Chem. 2022;70:11981-11993.
Wang CC, Chen HF, Wu JY, Chen LG. Stability of principal hydrolysable tannins from Trapa taiwanensis hulls. Molecules. 2019;24:365.
Mena P, Dall'Asta M, Calani L, Brighenti F, Del Rio D. Gastrointestinal stability of urolithins: an in vitro approach. Eur J Nutr. 2017;56:99-106.
Wu D, Cao M, Zhou J, et al. Lactobacillus casei T1 from kurut against Helicobacter pylori-induced inflammation and the gut microbial disorder. J Funct Foods. 2021;85:104611.
Song X, Zhang N, Xu H, Cao L, Zhang H. Combined preconditioning and postconditioning provides synergistic protection against liver ischemic reperfusion injury. Int J Biol Sci. 2012;8:707-718.
Ying L, Chaudhry MT, Xiao F, et al. The effects and mechanism of quercetin dietary supplementation in streptozotocin-induced hyperglycemic arbor acre broilers. Oxid Med Cell Longev. 2020;2020:9585047.
Niu J, Azfer A, Kolattukudy PE. Monocyte-specific Bcl-2 expression attenuates inflammation and heart failure in monocyte chemoattractant protein-1 (MCP-1)-induced cardiomyopathy. Cardiovasc Res. 2006;71:139-148.
Bergmann B, Jirholt P, Henning P, et al. Antibiotics with interleukin-15 inhibition reduce joint inflammation and bone erosions but not cartilage destruction in Staphylococcus aureus-induced arthritis. Infect Immun. 2018;86:e00960.
Huang J, Wan D, Li J, Chen H, Huang K, Zheng L. Histone acetyltransferase PCAF regulates inflammatory molecules in the development of renal injury. Epigenetics. 2015;10:62-72.
Cieslik KA, Trial J, Crawford JR, Taffet GE, Entman ML. Adverse fibrosis in the aging heart depends on signaling between myeloid and mesenchymal cells; role of inflammatory fibroblasts. J Mol Cell Cardiol. 2014;70:56-63.
Khan SR, Khan A, Byer KJ. Temporal changes in the expression of mRNA of NADPH oxidase subunits in renal epithelial cells exposed to oxalate or calcium oxalate crystals. Nephrol Dial Transplant. 2011;26:1778-1785.
Trastoy B, Klontz E, Orwenyo J, et al. Structural basis for the recognition of complex-type N-glycans by Endoglycosidase S. Nat Commun. 1874;2018:9.
Xie C, Li N, Wang H, et al. Inhibition of autophagy aggravates DNA damage response and gastric tumorigenesis via Rad51 ubiquitination in response to H. pylori infection. Gut Microbes. 2020;11:1567-1589.
Kawai M, Furuta Y, Yahara K, et al. Evolution in an oncogenic bacterial species with extreme genome plasticity: Helicobacter pylori east Asian genomes. BMC Microbiol. 2011;11:104.
Kim M, Sahu A, Hwang Y, et al. Targeted delivery of anti-inflammatory cytokine by nanocarrier reduces atherosclerosis in apo E (−/−) mice. Biomaterials. 2020;226:119550.
Occleston NL, O'Kane S, Goldspink N, Ferguson MW. New therapeutics for the prevention and reduction of scarring. Drug Discov Today. 2008;13:973-981.
Chen LH, Huang SY, Huang KC, et al. Lactobacillus paracasei PS23 decelerated age-related muscle loss by ensuring mitochondrial function in SAMP8 mice. Aging (Albany NY). 2019;11:756-770.
De-Lima-Junior JC, Souza GF, Moura-Assis A, et al. Abnormal brown adipose tissue mitochondrial structure and function in IL10 deficiency. EBioMedicine. 2019;39:436-447.
Winnik S, Lohmann C, Richter EK, et al. Dietary α-linolenic acid diminishes experimental atherogenesis and restricts T cell-driven inflammation. Eur Heart J. 2011;32:2573-2584.
Tumurkhuu G, Dagvadorj J, Porritt RA, et al. Chlamydia pneumoniae hijacks a host autoregulatory IL-1β loop to drive foam cell formation and accelerate atherosclerosis. Cell Metab. 2018;28:432-448.e434.
Alizada A, Khyzha N, Wang L, et al. Conserved regulatory logic at accessible and inaccessible chromatin during the acute inflammatory response in mammals. Nat Commun. 2021;12:567.
Zhao W, Wang L, Haller V, Ritsch A. A novel candidate for prevention and treatment of atherosclerosis: urolithin B decreases lipid plaque deposition in apoE−/− mice and increases early stages of reverse cholesterol transport in ox-LDL treated macrophages cells. Mol Nutr Food Res. 2019;63:e1800887.
Zheng D, Liu Z, Zhou Y, et al. Urolithin B, a gut microbiota metabolite, protects against myocardial ischemia/reperfusion injury via p62/Keap1/Nrf2 signaling pathway. Pharmacol Res. 2020;153:104655.
Piwowarski JP, Granica S, Kiss AK. Influence of gut microbiota-derived ellagitannins' metabolites urolithins on pro-inflammatory activities of human neutrophils. Planta Med. 2014;80:887-895.
Gao H, Huang X, Tong Y, Jiang X. Urolithin B improves cardiac function and reduces susceptibility to ventricular arrhythmias in rats after myocardial infarction. Eur J Pharmacol. 2020;871:172936.
Chen Q, Zhou Y, Zhou L, et al. TRPC6-dependent Ca2+ signaling mediates airway inflammation in response to oxidative stress via ERK pathway. Cell Death Dis. 2020;11:170.
Luo J, Xu T, Sun K. N6-methyladenosine RNA modification in inflammation: roles, mechanisms, and applications. Front Cell Dev Biol. 2021;9:670711.
Manzoor SS, Doedens A, Burns MB. The promise and challenge of cancer microbiome research. Genome Biol. 2020;21:131.
Landete JM. Ellagitannins, ellagic acid and their derived metabolites: a review about source, metabolism, functions and health-ScienceDirect. Food Res Int. 2011;44:1150-1160.
Schneider S, Carra G, Sahin U, Hoy B, Rieder G, Wessler S. Complex cellular responses of Helicobacter pylori-colonized gastric adenocarcinoma cells. Infect Immun. 2011;79:2362-2371.